REGAL is a Phase 3 randomized study testing GPS in AML patients who reached complete remission after a second round of rescue treatment. ・The main goal of the trial is to see whether the treatment …
Sellas Life Sciences stock has doubled this year – here’s why retail investors are still bullish
view original post